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Abstract
Background: The mucin MUC16 and the glycosylphosphatidylinositol anchored glycoprotein mesothelin likely facilitate the
peritoneal metastasis of ovarian tumors. The biochemical basis and the kinetics of the binding between these two glycoproteins
are not clearly understood. Here we have addressed this deficit and provide further evidence supporting the role of the MUC16-
mesothelin interaction in facilitating cell-cell binding under conditions that mimic the peritoneal environment.
Results: In this study we utilize recombinant-Fc tagged human mesothelin to measure the binding kinetics of this glycoprotein
to MUC16 expressed on the ovarian tumor cell line OVCAR-3. OVCAR-3 derived sublines that did not express MUC16 showed
no affinity for mesothelin. In a flow cytometry-based assay mesothelin binds with very high affinity to the MUC16 on the
OVCAR-3 cells with an apparent Kd of 5–10 nM. Maximum interaction occurs within 5 mins of incubation of the recombinant
mesothelin with the OVCAR-3 cells and significant binding is observed even after 10 sec. A five-fold molar excess of soluble
MUC16 was unable to completely inhibit the binding of mesothelin to the OVCAR-3 cells. Oxidation of the MUC16 glycans,
removal of its N-linked oligosaccharides, and treatment of the mucin with wheat germ agglutinin and erythroagglutinating
phytohemagglutinin abrogates its binding to mesothelin. These observations suggest that at least a subset of the MUC16-
asscociated N-glycans is required for binding to mesothelin. We also demonstrate that MUC16 positive ovarian tumor cells
exhibit increased adherence to A431 cells transfected with mesothelin (A431-Meso+). Only minimal adhesion is observed
between MUC16 knockdown cells and A431-Meso+ cells. The binding between the MUC16 expressing ovarian tumor cells and
the A431-Meso+ cells occurs even in the presence of ascites from patients with ovarian cancer.
Conclusion: The strong binding kinetics of the mesothelin-MUC16 interaction and the cell adhesion between ovarian tumor
cells and A431-Meso+ even in the presence of peritoneal fluid strongly support the importance of these two glycoproteins in
the peritoneal metastasis of ovarian tumors. The demonstration that N-linked glycans are essential for mediating mesothlein-
MUC16 binding may lead to novel therapeutic targets to control the spread of ovarian carcinoma.
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Background
The mucin MUC16 carries the peptide epitope CA125,
which is a prominent molecular marker for monitoring
the progression and recurrence of epithelial ovarian can-
cer (EOC) [1-3]. MUC16 is a very large mucin with an
average molecular weight between 2.5–5 million Da [2,4].
The peptide backbone of MUC16 is composed of the N-
terminal region, an extensive tandem repeat domain, and
a C-terminal region with a short cytoplasmic tail [2]. The
tandem repeat, a hallmark of all mucins, is composed of
18–60 repeats, each of which contains 156 amino acids
[2]. The N-terminal domain has been proposed to be
made up of 13,000 amino acids [4]. In addition to the
extensive protein structure, MUC16 is also heavily glyco-
sylated with both O-linked and N-linked oligosaccharides
[5].
Enumeration of the basic structure of MUC16 has led to
recent studies to define the biological properties of this
mucin. The over expression of MUC16 by many tumors of
epithelial origin suggest an important role for this mucin
in tumorigenesis. We have demonstrated that MUC16
inhibits the cytolytic responses of human natural killer
cells [6]. MUC16 also binds to galectin-1, a mammalian
lectin that is expressed on human immune cells [7]. These
studies suggest that one role of MUC16 is to prevent effi-
cient anti-tumor immune responses.
Another postulated function of MUC16 is to facilitate cell-
cell interactions. A recombinant fragment of MUC16
composed of the cytoplasmic region and a partial tandem
repeat domain binds to mesothelin, a glycoprotein that is
highly expressed by ovarian tumors and mesotheliomas
[8,9]. Mesothelin is normally expressed on the mesothe-
lial cells lining the peritoneal cavity [8]. In a heterotypic
cell adhesion assay, the epithelial ovarian tumor cells,
OVCAR-3, bind to the mesothelin expressing murine
endothelial-like cell line, LO [9]. Addition of increasing
concentrations of an anti-mesothelin antibody inhibited
the binding between these cells. These experiments sug-
gest that mesothelin may play an important role in the
metastasis of the ovarian tumors within the peritoneum.
Mesothelin is a 40 kDa glycoprotein that is initially syn-
thesized as a 70 kDa precursor [10]. Proteolytic cleavage
results in the release of a 32 kDa fragment called the meg-
akaryocyte potentiating factor [11]. The 40 kDa fragment
of this precursor is anchored to the cell surface by a glyco-
sylphosphatidyl inositol linkage and is referred to as mes-
othelin [8]. Initial experiments suggested a role for
mesothelin in cell adhesion events [8]. However, since
mesothelin knock-out mice do not exhibit any adverse
pathology, the exact function of this molecule is not clear
[12].
Considering the potential importance of the mesothelin-
MUC16 interaction in ovarian tumor metastasis within
the peritoneum, we have performed additional studies to
carefully define its molecular characteristics. The data pre-
sented conclusively shows that mesothelin binds to native
MUC16 expressed by the ovarian cancer cell line OVCAR-
3 and also to MUC16 isolated from the peritoneal fluid of
patients with EOC.
Here we provide firm evidence that N-linked oligosaccha-
rides of MUC16 are required for the binding of this mucin
to mesothelin. Kinetic analysis is provided to demonstrate
that mesothelin-MUC16 binding is a high affinity interac-
tion that increases cell adhesion between MUC16 and
mesothelin expressing cells. The importance of this obser-
vation to the peritoneal metastasis of ovarian tumors is
discussed.
Results
Mesothelin binds to native MUC16
Although mesothelin has been previously shown in direct
assays to bind a recombinant fragment of MUC16 [9], it
was important to conclusively demonstrate this interac-
tion with native forms of this mucin. MUC16 was par-
tially purified, by size exclusion chromatography, from
OVCAR-3 cell culture media and from the peritoneal fluid
of EOC patients as described in our earlier report [5].
These MUC16 samples showed strong binding to the
recombinant mesothelin tagged with the Fc fragment of
rabbit IgG (meso-Fc) in western blot overlay experiments
(Figure 1a). The banding pattern observed after overlaying
the membranes with meso-Fc was identical to that
obtained in blots where the mucin was detected with the
anti-MUC16 antibody, VK-8 (Figure 1b) [13,14]. We also
determined that this observation was not an artifact of
direct binding of the Fc portion to MUC16, as binding of
purified rabbit Fc to the mucin could not be detected by
western blotting (data not shown).
In our initial flow cytometry studies we observed that
meso-Fc would bind strongly to the OVCAR-3 cell surface.
Arguably, meso-Fc could bind to other ligands on the
OVCAR-3 surface in addition to MUC16. To determine
the specificity of meso-Fc binding to MUC16 on the cell
surface, we utilized stable sublines derived from the
parental OVCAR-3 cell line that did not carry MUC16 on
their cell surface. These MUC16 "Knock-down" cells, des-
ignated #7 and #9, express an intracellular scFv fragment
of the VK-8 antibody that captures the nascent MUC16
molecules in the endoplasmic reticulum, thereby inhibit-
ing the expression of this mucin on the cell surface
(Pinard et al, manuscript submitted). The #7 and #9
MUC16 knock-down cells showed only minimal affinity
for meso-Fc (Figure 2a). Control cells designated as #12,
which express a scFv fragment of a non-specific murineMolecular Cancer 2006, 5:50 http://www.molecular-cancer.com/content/5/1/50
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IgG, exhibited strong binding to meso-Fc (Figure 2b).
These results indicated that MUC16 was the only ligand
for meso-Fc on the OVCAR-3 cell surface. Similar results
were obtained (figure 2c–e) when the binding of meso-Fc
to these sublines was detected by using the anti-mesothe-
lin antibody MB [15].
The #9 cells upon continuous culture (usually after 6 pas-
sages) are "leaky" and may sometimes express higher
amounts of MUC16 (Figure 2d). Such an increased
expression of MUC16 on the #9 cells correlated with
enhanced meso-Fc binding to these cells (Figure 2d).
Mesothelin binds to MUC16 with strong affinity
Since MUC16 was shown to bind to mesothelin on the
surface of the OVCAR-3 cells, we utilized this specificity of
binding to devise a flow cytometry based assay to define
the affinity and kinetics of the mesothelin-MUC16 inter-
action. In the first experiment, the OVCAR-3 cells were
incubated with increasing amounts of MUC16 for 1 h
prior to analysis by flow cytometry. Meso-Fc binding to
the OVCAR-3 cells was concentration dependent with an
apparent dissociation constant (Kd) of 5 nM (Figure 3a).
Since the cell surface expression of MUC16 increases with
the amount of time that the OVCAR-3 cells are main-
Mesothelin binds to native MUC16 Figure 1
Mesothelin binds to native MUC16. (A) Meso-Fc binding to MUC16 samples from the ascites of patient #2 (100 U of 
CA125; lane 1) and from OVCAR-3 cells (500 U of CA125; lane 2) is shown (left panel). A control blot (right panel) with 
MUC16 from patient #2 (100 U of CA125; lane 1) and OVCAR-3 (500 U of CA125; lane 2) and meso-Fc (Lane 3) was overlaid 
with secondary antibody only. (B) For comparison, MUC16 from OVCAR-3 (100 U of CA125) was detected by VK-8 antibody. 
Note that since only 100 U (CA125) of OVCAR-3-derived MUC16 was loaded the banding pattern is identical to that of lane 1 
of (A).
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Mesothelin primarily binds to MUC16 on the OVCAR-3cell surface Figure 2
Mesothelin primarily binds to MUC16 on the OVCAR-3cell surface. (A)MUC16 expression on the parental OVCAR-
3 and the sublines #7, #9, and #12 was determined by flow cytometry using the VK-8 antibody. (B) Meso-Fc binding to the 
OVCAR-3 cells and the sublines #7, #9, and #12 was determined by flow cytometry using a GAR-FITC reporter antibody. (C-
E) The MB antibody was used to determine meso-Fc binding to #7 (C), #9 (D), and #12 (E) and compared to expression of 
native mesothelin and MUC16 on the surface of these cells.
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tained in culture, their capacity to bind meso-Fc amplifies
proportionately (data not shown). This effect results in
slight variations in the binding kinetics of meso-Fc. On
average, the Kd values range between 5–10 nM.
We routinely incubated the OVCAR-3 cells with meso-Fc
for 1 h to detect binding of this chimera to the cell surface.
In a time course study we have shown, however, that the
optimum binding of meso-Fc to the OVCAR-3 cell surface
is achieved within 5 mins (Figure 3b). Significant binding
of meso-Fc was observed even after an approximately 10 s
incubation of this chimera with the OVCAR-3 cells.
Together these experiments suggest that the mesothelin-
MUC16 binding is a very high affinity interaction that
occurs with rapid kinetics.
Inhibition studies using soluble MUC16 at half the molar
amount of meso-Fc reduced the binding of this chimera to
the OVCAR-3 cells by approximately 80% (Figure 3c).
However, residual binding of meso-Fc to the cell surface is
always observed even when a 5-fold molar excess of
MUC16 is used in these experiments (Figure 3c).
N-linked oligosaccharides of MUC16 are required for 
mesothelin binding
Considering its mucinous nature we next investigated if
mesothelin recognized the protein of the oligosaccharide
chains of MUC16. Periodate treatment of MUC16 under
conditions that selectively oxidize only the vicinal
hydroxyl groups present on the C8–C9 positions of termi-
nal sialic acids [16,17] had no effect on the binding of
meso-Fc to the mucin (Figure 4a). This result was sup-
ported by the observation that MUC16, upon desialyla-
tion with neuraminidase, retained its ability to bind to
meso-Fc (Figure 4b). On the contrary, oxidation of the vic-
inal hydroxyl groups present on the terminal sialic acids
as well as the internal monosaccharides of the entire gly-
can chains of MUC16 resulted in an almost complete loss
of meso-Fc binding to MUC16 (Figure 4a). MUC16 is
extensively glycosylated with both O-linked and N-linked
glycans [5]. The N-linked oligosaccharides were selectively
removed by treating MUC16 with peptide-N-glycosidase
(PNGaseF). Enzymatic removal of the N-linked glycans
corresponded with a decrease in molecular weight of
MUC16 as detected by western blot analysis (data not
shown). PNGaseF treated MUC16 almost completely lost
its ability to bind to meso-Fc (Figure 4c).
We next tested a panel of lectins for their ability to inter-
fere with the binding of mesothelin to MUC16. Since the
lectins could potentially bind to oligosaccharide chains
expressed on meso-Fc and hence complicate the analyses,
we employed recombinant non-glycosylated mesothelin
that was synthesized by bacterial cells. In western blot
overlay experiments, the lectin wheat germ agglutinin
(WGA) strongly inhibited the binding of bacterial mes-
othelin to MUC16 (Figure 4d). Appreciable inhibition
was also observed with the lectin erythroagglutinating
phytohemagglutinin (E-PHA), however, concanavalin A
(ConA) was unable to block this binding (Figure 4d).
The ConA ligand α-methyl mannopyranoside, does not
inhibit the binding of meso-Fc to MUC16 in western blot
overlay experiments (Figure 4e) and neither do the WGA
ligands N-acetylglucosamine and N-acetyllactosamine
[18,19] (Figure 5a). Chicken egg glycoproteins, ovotrans-
ferrin (conalbumin) and ovomucoid, that express the E-
PHA ligands bi- and tri-antennary bisecting type N-gly-
cans [20,21] weakly inhibited meso-Fc binding to the
OVCAR-3 cells (Figure 5b,c). The oligosaccharide
sequences recognized by WGA and E-PHA are also
expressed on human erythrocytes although this cell type
does not carry MUC16. Meso-Fc however, did not bind to
the erythrocytes (Additional File 1). We also determined
that the #7 and the #9 cells bound to WGA and E-PHA to
the same extent as the #12 and the parental OVCAR-3 cells
(Additional File 1). The #7 and #9 sublines cells have no
affinity for meso-Fc, however (Figure 1b).
A protein sequence analysis suggested that mesothelin is
primarily composed of helix-turn-helix repeats. The β-
pleated sheets that typically compose the C-type and I-
type lectins are not present in mesothelin. We have also
confirmed the earlier observation [9] that meso-Fc bind-
ing to MUC16 is independent of divalent cations (data
not shown).
Cell adhesion mediated via MUC16-mesothelin 
interaction
Interaction between human MUC16 and murine mes-
othelin was shown to mediate cell adhesion between the
OVCAR-3 and the LO cells, a murine cell line [9]. We
therefore decided to demonstrate if interaction between
human MUC16 and human mesothelin would also medi-
ate cell binding. For this purpose we utilized the #12 and
the #7 sublines along with human epidermoid epithelial
A431 cells expressing recombinant mesothelin (A431-
Meso+). To obtain quantitative data we performed a flow
cytometry assay where the formation of heterotypic dou-
blets was determined. The ovarian tumor cells and the
A431 cells were labeled with CellTracker Green and Cell-
Tracker Blue dyes, respectively. Heterotypic doublet for-
mation between the green and blue labeled cells was
measured by flow cytometry. When the #12 and the A431-
Meso+ cells were co-incubated, 25% of the total live cells
formed heterotypic doublets (Figure 6A; Additional File
2). The extent of heterotypic doublet formation was only
1.3% between the #7 and the A431-Meso+ cells. Very
small numbers (0.8%) of doublets were observed
between the #7 and the A431-Meso- cells. The #12 and theMolecular Cancer 2006, 5:50 http://www.molecular-cancer.com/content/5/1/50
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Kinetics of the mesothelin-MUC16 interaction Figure 3
Kinetics of the mesothelin-MUC16 interaction. (A) Binding of specified amounts of meso-Fc to OVCAR-3 was detected 
by flow cytometry. The left panel shows data for one representative experiment. Composite analysis of three independent 
experiments is shown in the panel on the right. Middle panel shows native expression of MUC16 on the OVCAR-3 cells used 
in this assay. (B) Time kinetics of meso-Fc (25 nM) binding to OVCAR-3 cells was determined by flow cytometry. After incuba-
tion with meso-Fc for the designated time intervals, the cell suspensions were diluted with 2 ml of buffer (a step that takes 
approximately 10 s) and analyzed. Raw flow cytometry data from one experiment is shown in panel on the left and composite 
analysis of two independent experiments is in the right panel. The middle panel shows expression of MUC16 on the OVCAR-
3 cells used in this experiment. (C) Inhibition of meso-Fc binding to OVCAR-3 cells by soluble MUC16 was also measured by 
using a flow cytometry assay. Meso-Fc preincubated with designated amounts of MUC16 was added to the cells. Binding was 
analyzed by flow cytometry. Left panel shows raw data for one experiment and panel on right shows composite data of two 
independent assays. The middle panels show VK-8 binding to the OVCAR-3 cells used in this experiment in the presence 
(green) or absence (blue) of soluble MUC16 (100 nM).
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A431-Meso-  combination produced approximately 8%
doublets suggesting that MUC16 may mediate cell adhe-
sion via mesothelin-independent mechanisms.
The ovarian cancer cells sloughing off from the tumor are
bathed in peritoneal fluid that contains high amounts of
MUC16 ([22]; Patankar, Belisle, and Gubbels, unpub-
lished observation). We therefore determined if the heter-
otypic doublet formation could occur even in the
presence of peritoneal fluid from EOC patients (#15 and
#24). Although the presence of ascites reduced the heter-
otypic cell adhesion between the #12 and the A431-Meso+
cells by approximately 33%, robust doublet formation
was still observed (Figure 6B; Additional File 2). The
ascites fluid from patients #15 and #24 had CA125 levels
of 45,600 U/ml and 83,600 U/ml. These values for CA125
correspond to 7 and 13 nM concentration of MUC16,
respectively (see Discussion). Since we routinely observe
that the concentration of CA125 in the peritoneal fluid is
between 20,000–100,000 U/ml the ascites samples we
have used in this study are highly representative.
Considering the relatively small effect of soluble MUC16
from the ascites on heterotypic doublet formation, we fur-
ther investigated the ability of the A431-Meso+ cells to
bind soluble MUC16. In this experiment, the A431-Meso+
cells were incubated with either purified MUC16 or with
ascites from EOC patient #15. Following incubation for 1
h, the amount of MUC16 on the A431-Meso+ cells was
measured by flow cytometry. Only a slight increase in cell
surface MUC16 was detected which was not proportional
to the amount of mesothelin expressed on these cells (Fig-
ure 7).
Finally, we also determined that the #12 cells were able to
form a higher number of homotypic doublets as com-
pared to the #7 cells (Figure 8). The mean of seven inde-
pendent experiments indicated that the homotypic
doublets for the #12 and the #7 cells were 35.2% and
26.7% (P < 0.0001) of the total live cells analyzed. The
interaction of mesothelin and MUC16 may enhance the
physical association of tumor cells and contribute to sphe-
roid formation. These homotypic doublets were observed
even in the presence of peritoneal fluid (Figure 8). The
A431-Meso+ cells upon incubation with MUC16 did not
exhibit any appreciable homotypic doublet formation
and neither did they bind to meso-Fc (data not shown).
This data is consistent with the observation that the A431-
Meso+ cells do not bind appreciable amounts of MUC16
(Figure 7).
Discussion
In a previous report, mesothelin was clearly shown to be
a binding partner for MUC16 [9]. Cell binding studies
suggested that mesothelin-MUC16 interaction could facil-
itate peritoneal metastasis of ovarian tumors. This
hypothesis is also supported by the observation that both
mesothelin and MUC16 are co-localized in immunohis-
tochemical studies of ovarian tumors. Understanding the
importance of MUC16-mesothelin binding may lead to
novel therapies to control the peritoneal spread of ovarian
tumors. With this in mind, a high throughput assay has
been developed to determine the ability of biological
agents to inhibit ovarian tumor metastasis [23].
To this date, the biochemical basis of the MUC16-mes-
othelin binding is not clearly understood. Our data
addresses this deficiency. Here, we have provided evi-
Mesothelin recognizes oligosaccharides expressed on  MUC16 Figure 4
Mesothelin recognizes oligosaccharides expressed on 
MUC16. (A) Meso-Fc binding to OVCAR-3-derived MUC16 
(200 U CA125/lane) after oxidation with 1 mM (lane 2) or 10 
mM (lane 4) SMP was detected in overlay experiments. 
Matching controls are in lanes 1 and 3, respectively. The 
blots were sequentially overlaid with meso-Fc, MN and a 
horseradish peroxidase conjugated secondary. (B) Meso-Fc 
binding to desailylated (lane 2) and non-desialylated (lane 1) 
MUC16 (150 U CA125/lane) from OVCAR-3 cells was 
determined in overlay experiments. (C) Meso-Fc binding to 
MUC16 (200 U CA125/lane) treated with PNGaseF (lane 2) 
or with buffer only (lane 1) was determined by Western blot 
overlay experiments. (D) Inhibition of bacterial mesothelin 
binding to OVCAR-3-derived MUC16 (200 U of CA125/blot) 
by ConA (blot 2), WGA (blot 3), and E-PHA (blot 4) 
detected in overlay experiments (D). No lectin was added in 
blot 1. (E) MUC16 from patient #2 (lane 1; 100 U of CA125) 
or from OVCAR-3 (lane 2; 500 U of CA125) were overlaid 
with meso-Fc in the presence (blot on left) or the absence 
(blot on right) of 0.5 M α-methylmannopyranoside. MN was 
used to detect meso-Fc binding in all experiments. Since full 
gel profiles have been shown in Fig. 1, only partial blots are 
shown here.
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dence that mesothelin has a very strong affinity for
MUC16 with an apparent Kd of approximately 5 nM. The
binding of these two molecules occurs with rapid kinetics
as demonstrated by our flow cytometry based assays. We
have conclusively shown that mesothelin interacts with
both soluble and cell surface associated forms of native
MUC16.
For the first time, we demonstrate that the N-linked gly-
cans of MUC16 are required for binding to mesothelin. In
this context it is important to note that Rump et al have
reported that inhibition of O-glycosylation of the
OVCAR-3 cells reduced the binding of mesothelin to the
cells [9]. Since no data was provided to support this obser-
vation it is not possible to directly compare the results of
this study with our observations. The importance of
MUC16 N-glycans in the binding to mesothelin suggests
at least two possibilities. First, the removal of the oligosac-
charides may result in perturbation of the mesothelin
binding site on the MUC16 protein backbone. This sug-
gestion is albeit difficult to conceptualize since the
MUC16 used in our western blot overlay experiments was
already denatured. The second possibility that is currently
under investigation in our laboratory is that mesothelin
acts as a lectin and directly binds to at least a subset of the
MUC16 associated N-glycans. If true, the inhibition of the
mesothelin-MUC16 binding by WGA and E-PHA suggests
that polylactosamine or bisecting type N-linked glycans
may be the potential ligands for mesothelin [18,19,24-
26]. The weak inhibition of mesothelin binding to
OVCAR-3 cells by ovomucoid and ovotransferrin sup-
ports the involvement of the bisecting type N-glycans.
Another possibility is that appropriate presentation of oli-
gosaccharide ligands is required for mesothelin binding.
WGA and E-PHA binding sites are abundant on human
erythrocytes (Gubbels and Patankar, unpublished results)
and the #7 and #9 cells (Additional File 1). Yet, meso-Fc
has no affinity for these cells. We propose that precise
positioning and/or expression of appropriate glycans in
high density is required for mesothelin to bind to candi-
date glycoprotein partners. MUC16, as a mucin, is exten-
sively glycosylated. These glycans are likely to be
presented in a repeating array on the tandem repeat
domain of MUC16 making it a very high affinity mesothe-
lin ligand.
Exhaustive studies that involve glycomic analysis of mes-
othelin bound MUC16 fragments will be required to
clearly define these oligosaccharide ligands. It should be
noted however, that mesothelin does not carry any of the
classical carbohydrate recognition domains that are found
in a majority of the mammalian lectins. Thus if mesothe-
lin directly binds to oligosaccharide ligands it may do so
via an as yet unidentified carbohydrate binding peptide
epitope.
Effect of glycoconjugates on mesothelin-MUC16 interaction Figure 5
Effect of glycoconjugates on mesothelin-MUC16 
interaction. (A) Binding of meso-Fc to OVCAR-3 cells was 
measured in the presence of 0.25 mM N-acetylglucosamine 
(GlcNAc) or N-acetyllactosamine (LacNAc) by flow cytome-
try. (B and C) Similarly the effect of ovomucoid (B) and ovo-
transferrin (C) on meso-Fc binding to OVCAR-3 was 
measured using the same technique. Meso-Fc binding was 
monitored by using the GAR-FITC reporter antibody.
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MUC16 expressing ovarian tumor cells form conjugates with mesothelin positive cells Figure 6
MUC16 expressing ovarian tumor cells form conjugates with mesothelin positive cells. (A) CellTracker green 
labeled sublines #12 and #7 were coincubated with either A431-Meso+ or A431-Meso- cells in PBS containing 1% BSA. The het-
erotypic doublets formation was measured by flow cytometry. The #7 and #12 sublines are represented in green, the A431 
cells are in blue and the heterotypic doublets are depicted in orange. The percentages of all live cells that form heterotypic 
doublets are shown for each plot. Cell debris is in red. (B) Heterotypic doublet formation between the sublines #12 and #7 
and the A431 cells in the presence of ascites from patient#15 is shown. The sublines are represented in green and the A431 
cells are in blue. Heterotypic doublets are in orange. The percentage of heterotypic doublets is shown for each plot. Cell 
debris is in red.
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Soluble MUC16 has a lower affinity for mesothelin Figure 7
Soluble MUC16 has a lower affinity for mesothelin. (A) A431-Meso+ cells were incubated with purified MUC16 (50,000 
U/ml). After 1 h, the amount of MUC16 on the cell surface was measured using the VK-8 antibody and a FITC labeled second-
ary. (B) Binding of A431-Meso+ cells to MUC16 from peritoneal fluid was measured by flow cytometry. The cells were cultured 
in the peritoneal fluid from patient #15 that contains (84,000 U of CA125/ml). MUC16 binding was detected using the VK-8 
and the FITC-labeled secondary antibodies. (C) The A431-Meso+ cells were labeled with MN and a FITC-conjugated second-
ary. Mesothelin expression was measured by flow cytometry.
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High concentrations of soluble MUC16 are present in the
peritoneal fluid of EOC patients ([22]; Patankar, Belisle,
and Gubbels, unpublished observations). Since the solu-
ble MUC16 may inhibit mesothelin-MUC16 binding, the
proposal that this interaction facilitates peritoneal metas-
tasis of ovarian tumors seems counter-intuitive. However,
having analyzed more than 30 samples of ascites derived
from individual EOC patients we have observed that the
concentration of CA125 in this fluid ranges from 20,000–
100,000 U/ml. Since the most highly purified MUC16
samples have a CA125 specific activity of 2.5 × 106 U/mg
of total protein and assuming that the average molecular
weight of MUC16 is 3 × 106 Da, these values of CA125 in
the ascites correspond to MUC16 concentrations of 1–10
nM. Inhibition studies indicate that MUC16 even when
used at 100 nM concentration was unable to completely
block the binding of meso-Fc to the OVCAR-3 cells (Fig-
ure 3c). Furthermore, there is a distinct possibility that
soluble MUC16 may have a lower affinity for mesothelin
than the cell surface associated counterpart of this mucin.
This is highlighted by our demonstration that A431-
Meso+  cells bind to only minor amounts of soluble
MUC16 (Figure 7). The proteolytic processing that occurs
when the MUC16 is shed from the surface of the tumor
cells or subsequent digestion of the N-linked glycans by
glycosidases in the peritoneal fluid may alter the soluble
MUC16 and make it a less effective ligand for mesothelin.
The lower affinity of mesothelin for soluble MUC16 also
makes it less likely that the mucin can act as a cross-link-
ing agent by attaching to mesothelin expressed on the
mesothelial and the ovarian tumor cells.
Binding of the tumor cells to the mesothelium via the
mesothelin-MUC16 interaction may provide a necessary
first step for metastasis. In this respect, the binding of mes-
othelin to the MUC16 glycans may be akin to the initial
binding of leukocytes to the inflamed endothelium that is
mediated by the selectins [27]. Tumor cell attachment to
the mesothelium may by itself not provide the strong
adhesive force required to maintain this heterotypic adhe-
sion. Instead, initial binding via this mechanism may lead
to recruitment of strong adhesive events mediated by
CD44, β-1 integrins, and other cell adhesion molecules
[28-30]. In vitro binding of ovarian cancer cells to the mes-
othelium is only partially inhibited by anti-CD44 and
anti-β-1 integrin antibodies [28,29]. It remains to be dem-
onstrated if simultaneous utilization of antibodies
directed against mesothelin, CD44 and β-1 integrins will
substantially inhibit binding of ovarian tumor cells to the
mesothelium.
MUC16-Mesothelin binding increases spheroid formation in ovarian tumor cells Figure 8
MUC16-Mesothelin binding increases spheroid formation in ovarian tumor cells. The #7 and the #12 sublines were 
labeled with CellTracker Green. After keeping the cells in suspension for 1 h in peritoneal fluid, the homotypic doublet forma-
tion was measured by flow cytometry. The singlet events are shown in pink and the doublets are in green. The percentage of 
live cells that form the homotypic doublets is shown for each plot.
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Mesothelin, like MUC16, is overexpressed by the ovarian
tumor cells [31]. Co-expression of both these molecules
may lead to further recruitment of additional tumor cells
to the site of metastasis. Thus, the tumor load at the site of
secondary metastasis may not only increase due to the
uncontrolled expansion of the cancer cells, but also by the
binding of additional tumor cells that are sloughed off
from the primary or secondary tumor sites. In this context
it is also important to note that ovarian cancer cells form
multicellular spheroids in the peritoneal fluid [32,33].
Our experiments demonstrating significantly higher
homotypic adhesions between the #12 cells as compared
to the MUC16 negative #7 cells (Figure 8) supports this
proposal.
A model showing the role of mesothelin-MUC16 interac-
tion in the peritoneal metastasis and ovarian tumor aggre-
gate is shown in Figure 9. Granted, other mechanisms
such as CD44 interactions are also important while stud-
ying the metastasis of ovarian tumors. However, since
their relationship with the mesothelin-MUC16 interac-
tions is not understood, these mechanisms are not
depicted in the proposed model.
Conclusion
In conclusion, we have provided new data on the interac-
tion between two glycoproteins, mesothelin and MUC16,
whose expression is highly upregulated by epithelial ovar-
ian tumors. The high affinity and specificity of this bind-
ing makes these two molecules excellent therapeutic
targets in the effort to prevent and control the peritoneal
metastasis of epithelial ovarian cancer. We will make con-
tinued efforts to determine the carbohydrate ligand on
MUC16 that is required for mesothelin binding and will
further investigate the biological function and signifi-
cance of these two interacting glycoproteins.
Methods
Cells, antibodies and other reagents
The anti-MUC16 antibodies OC125 and VK-8 were
obtained from Dr. Robert Bast and Beatrice Yin, respec-
tively. Anti-mesothelin antibodies MN and MB were
obtained as described previously [15]. Lectins were from
E-Y Laboratories, and all other regents were purchased
from Sigma of Fisher unless otherwise noted.
The OVCAR-3 cells were purchased from ATCC (Rock-
ville, MD). The OVCAR-3 derived CA125 knockdown sta-
ble sublines (#7 and #9) or control subline (#12)
expressing an anti-CA125 scFv fragment or nonspecific
scFv, respectively, were generated as described elsewhere
(Pinard et al, manuscript submitted). Blasticidin (0.5–
lµg/ml) was added in the media of the stable sublines to
maintain scFv expression. The A431-Meso+ and A431-
Meso- cells were obtained as described previously [34].
Isolation of native MUC16
MUC16 from OVCAR-3 cells was isolated as described in
our previous study [5]. MUC16 from ascites samples was
isolated as follows. Ascites from ovarian cancer patients
who had consented to participate in this study, was
obtained using standard surgical protocols. The protocols
for obtaining and processing of the ascites fluid samples
were approved by the Institutional Review Board. The
ascites fluid was centrifuged to remove cellular debris and
then stored at -20°C until use. Ascites (500 ml) was con-
centrated 5-fold in an Amicon concentrator fitted with a
100 kDa ultrafiltration membrane. The concentrated
ascites was separated in batches on a Sephacryl-500 HR
column. The column was eluted with 10 mM ammonium
bicarbonate containing 0.02% sodium azide. Fractions
were monitored for absorbance at 280 nm and the void
peak that contained the majority of the MUC16 was
pooled and purified once again on a second Sephacryl
500-HR column. The void peak was again pooled and
concentrated. The total protein in this peak was measured
by using the BCA (Pierce) reagent. The number of units of
CA125 in the sample was determined by using the stand-
ard clinical radioimmunoassay. The specific activity of
MUC16 derived from OVCAR-3 cells and the ascites was
approximately 1–2 × 106 and 5 × 105 U of CA125/mg of
total protein, respectively.
Preparation of recombinant mesothelin proteins
Recombinant bacterial mesothelin and mesothelin-Fc
fusion proteins were prepared as previously described
[34]. Briefly, the extracellular domain of human mesothe-
lin (GenBank accession number AY743922) was
expressed as a fusion protein with maltose-binding pro-
tein (MBP) using a modified pMAL-p2X vector (NEB, Bev-
erly, MA) containing the tobacco etch virus (TEV) cleavage
site. The fusion protein was directed to periplasm of
Escherichia coli. After TEV cleavage (Invitrogen, Carlsbad,
CA), the samples were applied to an amylase column for
removal of MBP. The same extracullular domain of mes-
othelin was also expressed as a fusion protein with Fc
using a modified pSecTag2 vector (Invitrogen, Carlsbad,
CA) containing rabbit IgG Fc. The plasmid was transfected
into HEK 293T cells with LipofectAMINE (Invitrogen).
The mesothelin-Fc proteins were harvested from the cul-
ture supernatant and purified with a Hi-trap protein A col-
umn (GE Healthcare). The purity of both bacterial
mesothelin and mesothelin-Fc fusion proteins was over
95%.
Western blot overlay experiments
MUC16 was separated on 10% SDS-PAGE gels and elec-
troblotted on a PVDF membrane. The membranes were
blocked for 1 h at 25°C with Tris buffered saline (TBS; 20
mM Tris containing 150 mM sodium chloride) containing
0.5% Tween 20 and 3% bovine serum albumin (BSA).Molecular Cancer 2006, 5:50 http://www.molecular-cancer.com/content/5/1/50
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The membrane was then overlaid overnight at 25°C with
0 or 1.9 µg of meso-Fc or recombinant bacterial mesothe-
lin in 10 ml of TBS containing 0.5% Tween 20 and 1.5%
BSA. The membranes were washed thoroughly with TBS
containing 0.5% Tween 20 and sequentially overlaid with
the anti-mesothelin antibodies (1:20 dilution) and horse-
radish peroxidase labeled goat anti-mouse IgG (Pierce;
1:20,000 dilution).
In some experiments following blocking with BSA, the
membranes were incubated with biotinylated lectins (10
µg/ml; purchased from E.Y. Laboratories) for 2 h at 25°C.
Following this incubation, the membranes were probed
sequentially with recombinant bacterial mesothelin, and
binding was detected using the MN antibody. To demon-
strate that the lectins used in this study bind to MUC16,
the blots were blocked with BSA and overlaid with the
respective biotinylated lectins. Binding of the lectins to
MUC16 was detected using peroxidase labeled avidin.
Chemical and enzymatic modification of the MUC16 
oligosaccharide chains
Oxidation of the MUC16 oligosaccharides by sodium
metaperiodate (SMP) was carried out as described previ-
ously [16,17]. Oxidation of the terminal sialic acids was
achieved by treatment of MUC16 with 1 mM SMP for 10
min at 4°C. To oxidize the vicinal hydroxyl groups in the
entire glycan chain, MUC16 was treated with 10 mM SMP
for 1 h at 25°C. Following oxidation the excess SMP was
neutralized by adding 10-fold molar excess of glycerol. In
matching controls the SMP was neutralized with glycerol
prior to addition to treatment with the mucin. Finally, the
test and control MUC16 samples were treated with 100
mM sodium borohydride.
MUC16 (500 U of CA125) was resuspended in 50 mM
sodium acetate buffer pH 5.5 in a total volume of 50 ml.
To this solution was added 1 U of type X neuraminidase
from Clostridium perfringens and the digestion was con-
ducted overnight at 37°C. A matching control sample of
MUC16 was incubated in the reaction buffer under iden-
tical conditions, except that no neuraminidase was added.
Digestion with neuraminidase was performed in dupli-
cate. To determine meso-Fc and VK-8 binding, MUC16
corresponding to 150 U of CA125 was analyzed by West-
ern blotting.
Removal of N-linked glycans was achieved by digesting
MUC16 (1000 U of CA125) with PNGaseF (Glyko). Reac-
tion buffers supplied by the manufacturer along with the
enzyme were used for this digestion. The reaction mixture
was incubated overnight at 37°C. Matching control was
treated under identical conditions, except that PNGaseF
was not added. Test and control MUC16 (250 U of
CA125) was used for Western blot analysis.
Meso-Fc binding to cells by flow cytometry
To determine binding to the cell surface, the cells (1 × 106)
were incubated with the designated concentration of
meso-Fc, on ice for 1 h. In most experiments, meso-Fc
bound to the cells was detected using a FITC-conjugated
GAR secondary antibody (1:1000 dilution). In some
experiments, after incubation with meso-Fc, the cells were
washed and incubated with MB (1:20 dilution) followed
by a FITC-labeled GAM secondary antibody. The cells
were analyzed on a FACSCalibur benchtop flow cytometer
(Becton Dickinson).
For the time kinetics, the OVCAR-3 cells were incubated
with meso-Fc (25 nM) for the designated time intervals.
Inhibition studies were conducted by incubating meso-Fc
(25 nM) with designated concentrations of either,
MUC16, N-acetylglucosamine, N-acetyllactosamine, ovo-
mucoid, or ovotransferrin for 1 h at 4°C. OVCAR-3 cells
(2.5 × 105) were added and allowed to incubate in this
Model for peritoneal metastasis of ovarian tumors Figure 9
Model for peritoneal metastasis of ovarian tumors. A 
model showing the importance of MUC16-mesothelin inter-
action in the peritoneal metastasis of ovarian tumors is 
shown.
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mixture for 1 h at 4°C. FITC-conjugated GAR secondary
antibody was used to detect meso-Fc binding to the cell
surface in all of these experiments. Following flow cytom-
etry, the mean fluorescence was determined and plotted
using the GraphPad Prism software package. The Kd and
Bmax values from the non-linear regression were used for
the Lineweaver-Burke plot.
Lectin binding experiments
The #12, #9, and #7 cells (500,000) were incubated with
4.5 µg/ml of biotinylated WGA and E-PHA PBS-BSA (100
µl). After incubation at 4°C for 1 h the cells were washed
twice with PBS-BSA and labeled with FITC-conjugated avi-
din. After 30 min incubation, the cells were washed and
analyzed by flow cytometry.
Mesothelin sequence analysis
Three different secondary structure prediction servers,
nnpredict [35], jpred [36], and 3d-pssm [37], all predicted
mesothelin to be made of a series of helices separated by
short coil segments, with no beta-sheet content. Three dif-
ferent fold recognition servers, 3d-pssm [37], genthreader
[38], and robetta [39], gave hits to proteins which had the
alpha-alpha superhelical structure made of the repeating
HEAT and ARM motifs [40].
Homotypic and heterotypic doublet formation assay
The A431-Meso+, A431-Meso-, #12 and #7 cells were har-
vested at confluency by trypsin digestion. Cells were
washed twice with PBS, then labeled with 1.25 pM Cell-
Tracker green (#12 and #7) or 190 pM Cell Tracker Blue
(A431-Meso+ and A431-Meso-) for 30 min at 37°C. Cells
were washed one time with PBS to remove excess dye. The
#7 and #12 cells were incubated in the presence or
absence of ascites with the A431-Meso+ or the A431-Meso-
cells for 1 h on ice. When ascites was not used the incuba-
tions were performed in PBS containing 1% BSA. The cell
suspensions were gently mixed on a cell shaker. Following
incubation, the cells were analyzed by flow cytometry on
a LSR-II (BD Biosciences). Vortexing or vigorous shaking
of the tubes was avoided prior to flow cytometry measure-
ments. During the flow cytometry measurement, the live
cells (cells that excluded propidium iodide) were gated.
Data from all of the events, singlet and doublet, was col-
lected for analysis. For heterotypic adhesions, the percent-
age of events staining for both the blue and the green dyes
were analyzed. Live homotypic adhesions were measured
using the width parameter on forward scatter.
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